Pablo J. Cagnoni's most recent trade in Incyte Corp. was a trade of 13,985 Common Stock done at an average price of $120.5 . Disclosure was reported to the exchange on Sept. 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Sale of securities on an exchange or to another person at price $ 120.49 per share. | 15 Sep 2026 | 13,985 | 183,200 (0%) | 0% | 120.5 | 1,685,053 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 71.93 per share. | 15 Sep 2026 | 9,233 | 206,418 (0%) | 0% | 71.9 | 664,130 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Sale of securities on an exchange or to another person at price $ 120.50 per share. | 15 Sep 2026 | 9,233 | 197,185 (0%) | 0% | 120.5 | 1,112,577 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2026 | 9,233 | 18,466 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 64.25 per share. | 15 Sep 2026 | 6,477 | 197,185 (0%) | 0% | 64.2 | 416,147 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2026 | 6,477 | 20,356 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.18 per share. | 15 Sep 2026 | 4,551 | 190,708 (0%) | 0% | 61.2 | 278,430 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2026 | 4,551 | 4,551 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2026 | 2,957 | 4,225 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.76 per share. | 15 Sep 2026 | 2,957 | 186,157 (0%) | 0% | 61.8 | 182,624 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Sale of securities on an exchange or to another person at price $ 125.56 per share. | 19 Aug 2026 | 10,801 | 183,200 (0%) | 0% | 125.6 | 1,356,174 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Sale of securities on an exchange or to another person at price $ 120.04 per share. | 12 Aug 2026 | 10,803 | 194,001 (0%) | 0% | 120.0 | 1,296,792 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Sale of securities on an exchange or to another person at price $ 122.69 per share. | 05 Aug 2026 | 10,640 | 204,804 (0%) | 0% | 122.7 | 1,305,422 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Sale of securities on an exchange or to another person at price $ 119.70 per share. | 31 Jul 2026 | 15,888 | 215,444 (0%) | 0% | 119.7 | 1,901,794 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2026 | 57,861 | 57,861 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2026 | 33,508 | 33,508 | - | - | Performance Shares | |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2026 | 13,403 | 231,332 (0%) | 0% | 0 | Common Stock | |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 114.88 per share. | 14 Jul 2026 | 17,969 | 222,879 (0%) | 0% | 114.9 | 2,064,279 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.09 per share. | 14 Jul 2026 | 4,950 | 217,929 (0%) | 0% | 115.1 | 569,696 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 95.59 per share. | 01 Jun 2026 | 25,469 | 240,848 (0%) | 0% | 95.6 | 2,434,582 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2026 | 31,517 | 266,317 (0%) | 0% | 0 | Common Stock | |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Sale of securities on an exchange or to another person at price $ 96.50 per share. | 17 Apr 2026 | 18,667 | 262,692 (0%) | 0% | 96.5 | 1,801,366 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 71.93 per share. | 17 Apr 2026 | 12,590 | 281,359 (0%) | 0% | 71.9 | 905,599 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2026 | 12,590 | 27,699 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 64.25 per share. | 17 Apr 2026 | 6,077 | 268,769 (0%) | 0% | 64.2 | 390,447 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2026 | 6,077 | 26,833 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, Global Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2026 | 27,892 | 262,692 (0%) | 0% | 0 | Common Stock | |
| Incyte | Pablo J. Cagnoni | President, R&D | Sale of securities on an exchange or to another person at price $ 94.24 per share. | 17 Mar 2026 | 18,667 | 234,800 (0%) | 0% | 94.2 | 1,759,178 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2026 | 11,501 | 32,910 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 64.25 per share. | 17 Mar 2026 | 11,501 | 253,467 (0%) | 0% | 64.2 | 738,939 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.18 per share. | 17 Mar 2026 | 7,166 | 241,966 (0%) | 0% | 61.2 | 438,416 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2026 | 7,166 | 9,102 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2026 | 28,475 | 28,475 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2025 | 43,846 | 43,846 | - | - | Performance Shares | |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2025 | 39,471 | 39,471 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2025 | 17,538 | 234,800 (0%) | 0% | 0 | Common Stock | |
| Incyte | Pablo J. Cagnoni | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.25 per share. | 14 Jul 2025 | 2,628 | 217,262 (0%) | 0% | 68.3 | 179,361 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.98 per share. | 14 Jul 2025 | 1,280 | 219,890 (0%) | 0% | 70.0 | 89,574 | Common Stock |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 40,289 | 40,289 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 44,411 | 44,411 | - | - | Employee Stock Option (right to buy) | |
| Incyte | Pablo J. Cagnoni | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 19,851 | 221,919 (0%) | 0% | 0 | Common Stock | |
| Incyte | Pablo J. Cagnoni | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 64.25 per share. | 15 Jul 2024 | 749 | 221,170 (0%) | 0% | 64.2 | 48,123 | Common Stock |
| Incyte | Pablo Cagnoni J. | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 21,843 | 21,843 | - | - | Employee Stock Option (right to buy) | |
| Fusion Pharmaceuticals Inc | Pablo J. Cagnoni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) |